SCHEMBL15543002

SCHEMBL15543002

CCC(=NOCc1ccc(S(C)(=O)=O)cc1)c1ccc(OCC(=O)N2CCOCC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 5/20 0.55
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 5/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HPGD P15428 3/20 0.49
TP53 P04637 1/20 0.49
CYP2C9 P11712 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
POLB P06746 1/20 0.49
LMNA P02545 5/20 0.49
GAA P10253 1/20 0.48
KDM4E B2RXH2 1/20 0.48
HTT P42858 1/20 0.48
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15543000 1.00 FKBP1A (0.55) FKBP1AL3MBTL1ALDH1A1NPSR1HPGD
SCHEMBL15543267 0.90 TP53 (0.52) L3MBTL1ALDH1A1HPGDTP53POLB
SCHEMBL15543314 0.90 TP53 (0.52) L3MBTL1ALDH1A1HPGDTP53POLB
SCHEMBL16468364 0.85 FKBP1A (0.55) FKBP1AALDH1A1HPGDSMN1; SMN2POLB
SCHEMBL15543164 0.85 FKBP1A (0.55) FKBP1AALDH1A1HPGDSMN1; SMN2POLB
SCHEMBL12476507 0.80 KMT2A (0.43) L3MBTL1ALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL12476509 0.80 KMT2A (0.43) L3MBTL1ALDH1A1SMN1; SMN2LMNAGAA
SCHEMBL15543990 0.79 ALDH1A1 (0.62) FKBP1AALDH1A1HPGDCYP2C9SMN1; SMN2
SCHEMBL15543992 0.79 ALDH1A1 (0.62) FKBP1AALDH1A1HPGDCYP2C9SMN1; SMN2
SCHEMBL15543994 0.78 FKBP1A (0.60) FKBP1AALDH1A1HPGDCYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2864309-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES Cadila Healthcare Limited (IN) 2015-04-29 EP claimed
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-19 US claimed
WO-2014002105-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LIMITED (IN) 2014-01-03 WO claimed
EP-2864309-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES Cadila Healthcare Limited (IN) 2015-04-29 EP disclosed
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LTD (IN) 2015-02-19 US disclosed
WO-2014002105-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES CADILA HEALTHCARE LIMITED (IN) 2014-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051144-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES PCSK9, HMGCR, CETP FKBP1A 1033/4885L3MBTL1 2707/4885ALDH1A1 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.